Artificial intelligence in pharmaceutical industry expected to reach $13.46 billion by 2032

The global Artificial Intelligence (AI) in Pharmaceutical Market was valued at USD 1.73 billion in 2024 and is projected to reach USD 13.46 billion by 2032, growing at a CAGR of 29.33%. AI technologies like machine learning are transforming drug discovery and clinical trials, revolutionizing the pharmaceutical industry.

The U.S. AI in pharmaceutical market was estimated at USD 0.47 billion in 2024 and is expected to reach USD 3.67 billion by 2032, with a CAGR of 29.19%. The U.S. leads in AI adoption in North America, driven by a strong pharmaceutical and technology ecosystem.

In 2024, the drug discovery segment dominated the AI in pharmaceutical market with a 64.29% market share, revolutionizing early-stage drug development and improving success rates. Machine learning led the market with a 48.24% share, offering unmatched capabilities in analyzing biomedical data.

The software segment held the largest share in the AI in pharmaceutical market in 2024 at 55.10%, providing tools for data processing and predictive modeling. North America led the market with a 36.16% share, while Asia-Pacific is expected to grow at the highest CAGR of 30.12% due to increased healthcare expenditure.

SNS Insider is a leading market research and consulting agency, providing clients with accurate market data and insights to make informed decisions. Their research on AI in pharmaceuticals highlights the rapid growth and impact of AI technologies in transforming the pharmaceutical industry.

Read more at GlobeNewswire: Artificial Intelligence (AI) in Pharmaceutical Market to